Assessing the impact of levetiracetam and sodium valproate monotherapy on serum 25-hydroxy vitamin D levels in pediatric epilepsy: Insights from a leading tertiary care hospital in Haldwani
DOI:
https://doi.org/10.71152/ajms.v16i12.4865Keywords:
Levetiracetam; Sodium valproate; 25-hydroxy vitamin D; Seizures; Prospective interventional study; Pediatrics; MonotherapyAbstract
Background: Epilepsy, as a prevalent chronic neurological disorder, requires prolonged therapeutic interventions, which may expose pediatric patients undergoing anticonvulsant treatment to potential risks associated with Vitamin D deficiency and compromised bone health. This research delves into the impact of Levetiracetam (LEV) and Sodium Valproate (VPA), two commonly prescribed antiepileptic medications, on bone health.
Aims and Objectives: To study the effects of LEV and sodium VPA monotherapy on serum 25-hydroxy vitamin D levels in pediatric patients with epilepsy (1–16 years).
Materials and Methods: Within a prospective interventional investigation, a total of 148 newly diagnosed pediatric epilepsy patients aged between 1 and 16 years were recruited and segregated into two cohorts: One administered LEV (n=74) and the other receiving Sodium VPA (n=74). The study assessed serum Vitamin D levels, in conjunction with Calcium, Phosphorous, and ALP, both before and after a 6 months period of monotherapy.
Results: Following the intervention, it was observed that 72.9% of patients treated with Sodium VPA demonstrated a decline in Vitamin D levels, among whom 24.3% displayed significant Vitamin D insufficiency (P<0.001). In contrast, 43.2% of individuals receiving LEV exhibited decreased Vitamin D levels, with only 6.2% manifesting Vitamin D insufficiency (P=0.004), indicating a comparatively milder impact on bone health.
Conclusion: The findings suggest that Sodium VPA monotherapy substantially disrupts bone metabolism when juxtaposed with LEV, thus implying that the latter may represent a safer alternative concerning bone health. This study accentuates the critical importance of routine monitoring of Vitamin D levels and potential supplementation for pediatric patients undergoing treatment with Sodium VPA to alleviate the associated bone health hazards.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
